0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Original Article |

Gene Variants of Brain Dopamine Pathways and Smoking-Induced Dopamine Release in the Ventral Caudate/Nucleus Accumbens FREE

Arthur L. Brody, MD; Mark A. Mandelkern, MD, PhD; Richard E. Olmstead, PhD; David Scheibal, BS; Emily Hahn, BA; Sharon Shiraga, BS; Eleanor Zamora-Paja, BS; Judah Farahi, PhD; Sanjaya Saxena, MD; Edythe D. London, PhD; James T. McCracken, MD
[+] Author Affiliations

Author Affiliations: Department of Psychiatry and Biobehavioral Sciences (Drs Brody, Saxena, London, and McCracken and Mr Scheibal and Mss Hahn, Shiraga, and Zamora-Paja) and Department of Molecular and Medical Pharmacology (Dr London), University of California, Los Angeles; Positron Emission Tomography Center, Greater Los Angeles VA Healthcare System, Los Angeles (Drs Brody, Mandelkern, Olmstead, and Farahi and Mr Scheibal and Ms Hahn); and Department of Physics, University of California, Irvine (Dr Mandelkern).


Arch Gen Psychiatry. 2006;63(7):808-816. doi:10.1001/archpsyc.63.7.808.
Text Size: A A A
Published online

Context  Preclinical studies demonstrate that nicotine administration leads to dopamine release in the ventral striatum. However, human studies reveal considerable interindividual variability in the extent of smoking-induced dopamine release.

Objective  To determine whether common gene variants of the brain dopamine pathway explain this observed phenotypic variability in humans.

Design  Blood samples were drawn to determine gene variants of dopamine system components, and positron emission tomography scanning with the radiotracer raclopride labeled with radioactive carbon (11C) was performed to measure smoking-induced dopamine release.

Setting  Academic brain imaging center.

Participants  Forty-five tobacco-dependent smokers.

Interventions  Subjects either smoked a cigarette (n = 35) or did not smoke (n = 10) during positron emission tomography scanning.

Main Outcome Measures  Gene variants of dopamine system components (the dopamine transporter variable nucleotide tandem repeat, D2 receptor Taq A1/A2, D4 receptor variable nucleotide tandem repeat, and catechol-O-methyltransferase Val158Met polymorphisms) and change in [11C]raclopride binding potential in the ventral caudate/nucleus accumbens on positron emission tomography scans.

Results  For subjects who smoked during scanning, those with at least one 9 allele of the dopamine transporter variable nucleotide tandem repeat, fewer than 7 repeats of the D4 variable nucleotide tandem repeat, and the Val/Val catechol-O-methyltransferase genotype had greater decreases in binding potential (an indirect measure of dopamine release) with smoking than those with the alternate genotypes. An overall decrease in ventral caudate/nucleus accumbens binding potential in those who smoked compared with those who did not smoke was also found but was smaller in magnitude than previously reported.

Conclusions  Smokers with genes associated with low resting dopamine tone have greater smoking-induced (phasic) dopamine release than those with alternate genotypes. These findings suggest that dopamine system genotype variabilities explain a significant proportion of the interindividual variability in smoking-induced dopamine release and indicate that smoking-induced dopamine release has a genetic predisposition.

Figures in this Article

A common pathway for the reinforcing properties of most, if not all, addictive drugs is the mesolimbic brain dopamine (DA) system.14 In laboratory animal studies, the reinforcing property of nicotine has repeatedly been linked to DA release in the nucleus accumbens (NAc).514 Recent small studies of human smokers have used raclopride labeled with radioactive carbon (11C) with positron emission tomography (PET) to assess change in DA concentration in response to smoking. These studies have generally supported the association between smoking and DA release, especially the relief from craving15 and hedonic responses16 that smokers experience when smoking. However, considerable unexplained interindividual variability in smoking-induced DA release was reported in these studies.

The high heritability of nicotine dependence17 and differences in individual sensitivity to the reinforcing properties of smoking implicate the influence of genetic differences on positive reinforcement from smoking.18 In the primary analysis of the present study, we sought to determine if known genetic variability in components of the brain DA pathway would help explain observed phenotypic variability in smoking-induced DA release found among human smokers. Although others have associated genetic variability with overall D2 dopamine receptor densities,1922 we are aware of no prior studies that examined the link between DA genetic variability and DA release in humans. For this initial study, we restricted our examination to those well-characterized gene variants with reported functional effects while recognizing that many other genes could contribute to variation in smoking-induced DA release.

Within the mesolimbic DA pathway, nicotine stimulates nicotinic acetylcholine receptors on neurons of the ventral tegmental area that project to the NAc and release DA, resulting in positive reinforcement.9,23,24 Genotypic (and associated phenotypic) variation of any of the components of this pathway could affect the degree of smoking-induced DA release in individual smokers. From a large number of potential genes of interest, specific gene variants were chosen for analysis from well-studied parts of brain DA pathways, namely (1) the DA transporter (DAT),25 (2) the D2 dopamine receptor (DRD2) (a presynaptic and postsynaptic receptor26 that is activated indirectly by even low concentrations of nicotine27), (3) the D4 dopamine receptor (DRD4) (a receptor that is expressed in low levels in the basal ganglia but may modulate excitatory neurotransmission28), and (4) the enzyme catechol-O-methyltransferase (COMT).29

Four genetic variants were chosen from these DA system components based on substantial evidence of functional consequences of these variants, possible association with risk for nicotine dependence, and/or influence on brain DA system regulation. For DAT, the variable number of tandem repeat (VNTR) polymorphism of the 3′ untranslated region (SLC6A3)30 was selected because of reports linking the 10-repeat allele with risk for conditions associated with smoking behavior, namely attention-deficit/hyperactivity disorder,31 hyperactivity,32 and reward dependence.33 Studies using single photon emission computed tomography have demonstrated associations between the 10-repeat allele and increased,34 decreased,35,36 or unaltered3739 DAT density (compared to alternate genotypes) with the larger (sample-size) studies demonstrating decreased or unaltered DAT density. If subjects with the 10-repeat allele indeed have decreased DAT density, we hypothesize that such subjects would have higher tonic levels of intrasynaptic DA and less phasic DA release in response to smoking.

For DRD2, A1/A2 allelic variation of Taq1 was selected because the A1 allele is associated with low DRD2 density,19,20,4042 increased likelihood of smoking behavior overall,43 progression to higher levels of smoking by adolescents,44 less positive responsiveness to bupropion hydrochloride45,46 (a medication with dopaminergic properties) or other treatments47 in smokers attempting to quit, and greater feelings of food reward following smoking cessation.48 Because the A1 allele is associated with decreased DRD2 density and function, and the DRD2 receptor is associated with inhibition of DA release,49,50 we hypothesized that subjects with the A1 allele would have greater DA release (due to less inhibition) than those with the alternate genotype.

For DRD4, variation in the 48–base pair (bp) VNTR in exon 3 was chosen based on the association of the 7-repeat allele with a reduced ability of DA to inhibit cAMP formation,51 reduced effectiveness of DA-releasing medications,52 and links with smoking behavior.53 Because DRD4 stimulation results in sensitization to a DA-releasing drug54 and blockade in the NAc results in diminished DA release,55 we hypothesized that subjects with the 7-repeat allele of DRD4 (having less DRD4 function) would have less smoking-induced DA release than subjects with the alternate genotype.

For COMT, we chose the 1947A>G (Val158Met) polymorphism because the Val substitution is associated with 3-fold to 4-fold higher enzyme activity56 as well as substance abuse57 and the personality traits novelty seeking and reward dependence.58 Additionally, a recent review of the functional effects of the COMT polymorphism59 concluded that the Met allele (low enzyme activity) results in increased levels of tonic DA and reciprocal reductions in phasic DA released in subcortical regions. Based on these reports, we hypothesized that subjects with the Met allele would have less smoking-induced DA release than subjects with the alternate genotype.

The 4 gene variants were studied with the recognition that research linking genetic variants with smoking and/or the brain DA system is an evolving field, and only modest links exist in the scientific literature between genotype and smoking.60,61 Other genotypes (such as α4β2 nicotinic acetylcholine receptor,62 dopamine β hydroxylase,63 and 5-HTT60 functional polymorphisms) are certainly candidates for associations with smoking-induced DA release; however, we felt that evidence for including these genotypes was not as strong as for the ones selected. We also recognize that some of the DA genotypes chosen here have had negative reports for associations with smoking,6467 and some have had conflicting results regarding which allelic variants (if any) are associated with smoking.6871

In addition to the primary analysis of this study (genotype/PET associations), we also tested for evidence of smoking-induced DA release as we have in the past15 with the present study having a larger sample of smokers and subjects being scanned on a newer PET scanner with improved sensitivity.

SUBJECTS AND STUDY OVERVIEW

Forty-five otherwise healthy adult (21-65 years old) cigarette smokers (15-40 cigarettes per day) were interviewed with standardized questions; filled out rating scales related to cigarette usage, mood, and personality; had blood drawn for genetic testing; underwent [11C]raclopride PET scanning and either smoked a cigarette (n = 35) or did not smoke (n = 10) during the scan; and underwent structural magnetic resonance imaging (MRI) (to aid in interpretation of the PET scans). Subjects completed genetic testing, PET scanning, and administration of rating scales on a single afternoon and underwent structural MRI on a separate morning within 1 week of PET scanning. The present study represents a new group of subjects that have no overlap with those in our previous report.15

Subjects were screened initially during a telephone interview in which medical, psychiatric, and substance abuse histories were obtained without personal identifiers. All subjects who qualified were assessed in person using screening questions from the Structured Clinical Interview for DSM-IV (SCID).72 Inclusion and exclusion criteria were the same as in our previous report with the central inclusion criterion being DSM-IV nicotine dependence and subjects being excluded for any history of an Axis I psychiatric or substance abuse/dependence diagnosis other than nicotine dependence. After a complete description of the study was provided to the subjects, written informed consent was obtained using forms approved by the local institutional review board.

GENETIC TESTING

Blood samples were collected and genomic DNA was extracted from whole blood with the Qiagen Kit using the manufacturer's protocol (Qiagen, Valencia, Calif).

The DAT1 (SLC6A3) 40-bp repeat polymorphism was genotyped as described elsewhere.48 The DRD2 TaqA1 polymorphism and the COMT Val108/158Met polymorphism were genotyped by polymerase chain reaction, restriction digest, and electrophoresis according to published methods.19,56 The DRD4 48 bp repeat polymorphism was genotyped as follows, based on a modification of published methods. Polymerase chain reaction amplification of 50 ng of genomic DNA was performed in 20 μL reactions containing 6pM deoxynucleoside triphosphate, 8 nmol of forward and reverse primers, 0.2 μM Tris (8.4 pH), 1 μM potassium chloride, 30 pmol of magnesium, 1× Q solution, and 1 U of HotStar Taq DNA polymerase (Qiagen). The primer sequences used were DRD4F, 5′-CTA CCC TGC CCG CTC ATG-3′; DRD4R, 5′-CCG GTG ATC TTG GCA CGC-3′. Using the MJ Research Tetrad thermal cycler (Bio-Rad, Hercules, Calif), DNA was denatured at 95°C for 15 minutes, followed by 10 cycles of 95°C for 30 seconds, 66°C for 30 seconds, and 72°C for 90 seconds and 25 cycles of 95°C for 30 seconds, 55°C for 30 seconds, and 72°C for 90 seconds, followed by a final extension at 72°C for 10 minutes. Ten μL of polymerase chain reaction products were electrophoresed in 3.5% Nusieve Agarose (Cambrex, Baltimore, Md) in 1X TBE (Tris/borate/EDTA) buffer for approximately 4 hours at 70 V. The gels were stained with ethidium bromide, and alleles were determined by comparison with molecular weight standards and with control individuals with previously determined genotypes.

PET (AND MRI) SCANNING AND IMAGE ANALYSIS

Scanning sessions with PET and MRI followed the same protocol as in our previous report15 with the exception that scans for the current group were performed on a newer PET scanner (described later in this section). Positron emission tomography scanning consisted of a single [11C]raclopride bolus-plus-continuous-infusion PET session. Subjects were instructed to smoke per their usual habit on the morning of the PET session and to smoke a cigarette immediately prior to the test session, which began at noon. Between noon and 1:45 pm, subjects were interviewed and they filled out rating scale questionnaires and other measures. The rating scales included screening questions from the Structured Clinical Interview for DSM-IV,72 the Fagerström Test for Nicotine Dependence,73,74 the Urge to Smoke (UTS) scale,75 the Spielberger State-Trait Anxiety Index,76 and the Hamilton Depression77 and Anxiety78 rating scales. Exhaled carbon monoxide levels were measured prior to [11C]raclopride injection using a MicroSmokerlyzer (Bedfont Scientific Ltd, Kent, United Kingdom) to make a rough estimate of recent smoking level. In addition to these prescanning ratings, cigarette craving (UTS) and state anxiety (Spielberger State-Trait Anxiety Index) levels were monitored at 3 other points during PET scanning. Only the UTS scores were analyzed with the PET data (as discussed later in this section) while other rating scales were administered to ensure low levels of psychiatric symptoms in the study sample.

At 1:45 pm, subjects had a 20-gauge intravenous catheter placed and were positioned on the PET scanner (for acquisition of planes parallel to the orbital-meatal line) at 2 pm. Scanning was initiated at 2:10 pm with a slow bolus injection of 185 MBq [11C]raclopride in 20 mL normal saline over a 60-second period followed by continuous infusion of the tracer (111 MBq/h) for the remainder of the testing session. This bolus-plus-continuous-infusion method was performed as described in prior studies.79,80 Brain scans were acquired continuously for the next 50 minutes.

At 3 pm, subjects were taken off the scanner with the infusion still running and had a 10-minute break in an outdoor area adjacent to the PET scanning room. Thirty-five subjects smoked a regular cigarette (either their favorite brand or a standard study cigarette) during this period; the remaining subjects stood in the same outdoor area but did not smoke during scanning as a control condition (assignment to the smoking or no-smoking condition was random with a ratio of 4:1). The 3-hour period of abstinence prior to the break was chosen based on the finding that craving starts to peak at this time in nicotine-dependent smokers.81 A study investigator (A.L.B. or R.E.O.) monitored subjects continuously during the break. After the break, subjects were quickly repositioned (<1 minute) in the scanner using a preplaced mark on their forehead and a laser light from the scanner. Subjects were then scanned for 30 minutes longer.

Subjects were scanned on a GE Advance NXi scanner (General Electronic Medical Systems, Milwaukee, Wis) with 35 slices in 3-dimensional mode. We prepared [11C]raclopride using an established procedure.82,83 Positron emission tomography scans were acquired as 10 prebreak and 6 postbreak 5-minute frames. Attenuation correction scanning was performed with the germanium rotating rod source built into the GE scanner for 5 minutes following the postbreak scan, and this attenuation correction was applied to both prebreak and postbreak scans.

An MRI scan of the brain was obtained with the following specifications: 3-dimensional Fourier-transform spoiled-gradient-recalled acquisition; repetition time, 30 ms; echo time, ms; 30° angle; 2 acquisitions; 256 × 192 view matrix. The acquired volume was reconstructed as 90 contiguous 1.5-mm-thick transaxial slices.

Coregistration of PET scans to MRI scans was performed using the automated image registration method84 within MEDx 3.3 (Sensor Systems Inc, Sterling, Va). The prebreak (0- to 50-minute) and postbreak (60- to 90-minute) scans were coregistered to the MRI separately. Individual 5-minute time frames were then coregistered to MRI scans using the transformation matrix parameters from the coregistration of the summed images.

Regions of interest were drawn on MRI and transferred onto the coregistered PET scan frames. Region-of-interest placement on each frame was verified by visual inspection by the region drawers (D.S. and E.H.) and the principal investigator. For this study, the volume-of-interest (VOI) value used for statistical analysis was the volume-weighted mean of left and right ventral caudate (VCD) regions of interest (including the NAc) (Figure 1), consisting of 3 slices each, resulting in a single VOI value for each 5-minute frame of PET scanning. Volume-weighted means of left and right dorsal caudates and putamen were drawn as additional regions as in our prior report.15 The entire cerebellum was drawn as a reference region. Binding potential (BP) for the VCD/NAc (and other striatal regions) was calculated using the simplified reference tissue model85 with BP = B′max/Kd = CVCD/NAc/Ccerebellum − 1, where C is radioligand concentration. Binding potential was determined for each 5-minute PET frame, and mean BP values were compared between the frames before (40-50 minutes) and after (60-90 minutes corrected for radiotracer physical decay) the break in scanning. These time frames are almost identical to those recommended and used as optimal for maximizing the signal-to-noise ratio in studies of the [11C]raclopride bolus-plus-continuous-infusion method.86,87 This method assumes 40 minutes for the bolus plus infusion to reach a near steady state.80,86,87 It also assumes that DA concentration will remain elevated throughout the 30-minute postsmoking scan as indicated by animal microdialysis5,8890 and imaging91 studies of nicotine administration. A single primary ventral striatum VOI was used to avoid multiple comparison corrections, which would reduce the power of this analysis.

Place holder to copy figure label and caption
Figure 1.

Magnetic resonance image (MRI)/positron emission tomography (PET) coregistration, showing regions of interest drawn on MRI and transferred to a coregistered PET image with raclopride labeled with radioactive carbon (11C). VCD/NAc indicates ventral caudate/nucleus accumbens.

Graphic Jump Location
STATISTICAL ANALYSES
General

Because of the possibility of type I statistical error in a large data set such as this one (which includes gene variant data for many genes, PET data for multiple regions, and rating scale and demographic data), we limited statistical tests to the fewest possible relevant variables based on prior research. For genetic variant data, 4 gene variants were studied, and each was used to divide the study group into 2 subgroups. The 4 genetic variants (described earlier in the article) and the subgroups based on these variants were the DAT VNTR (9/9 and 9/10 vs 10/10), DRD2 Taq1 (A1/A1 and A1/A2 vs A2/A2), DRD4 VNTR (less than 7 repeats vs 7 or more repeats), and COMT (Met/Met and Met/Val vs Val/Val) polymorphisms. For PET data, the only variable used was percentage change in BP for the average of left and right VCD/NAc VOIs from the 10-minute period before to the 30-minute period after the break. A single VOI BP value was felt to be sufficient based on our prior report that demonstrated nearly identical BP changes for the left and right VCD/NAc15 and similar changes across all striatal regions. Statistical tests described in the following sections were performed with SPSS version 11.5 (SPSS, Chicago, Ill).

Associations Between Genetic Variants and Smoking-Induced DA Release

For the primary analysis here, an overall univariate analysis of variance was performed for the 35 subjects who smoked during scanning with percentage change in VCD/NAc BP as the dependent variable and the 4 genetic variants as between-subject factors without interactions. Each genetic variant subgroup's VCD/NAc BP percentage change was examined to assess which genetic variants had greater and lesser degrees of smoking-induced DA release. To further characterize results of this primary analysis, t tests (2-tailed) were performed comparing the subgroups of the genotypes found significant in the preceding analysis to determine if they differed significantly in levels of smoking (cigarettes per day), number of years smoking, or change in craving (UTS score) from before to after smoking.

Study of Smoking-Induced DA Release

In our previous study,15 an unexpectedly large percentage change in ventral striatal BP with smoking was found in a small sample of subjects who smoked during scanning (n = 10). Here, we studied a larger group of subjects using a newer PET scanner and attempted to again test the hypothesis that smoking would result in greater reductions in VOI BP than a nonsmoking control. For this analysis, a t test (2-tailed) was performed for percentage change in VCD/NAc BP in the group that smoked (n = 35) vs the control group that did not smoke (n = 10). Correlation coefficients were also determined between percentage change in VCD/NAc BP and change in UTS (craving) score for the group that smoked to seek to again demonstrate an association between change in the indirect measure of DA release (change in VCD/NAc BP) and change in craving (UTS score).15

GENERAL SUBJECT CHARACTERISTICS

The study population consisted of adults (mean ± SD age, 36.6 ± 10.6 years), who smoked a mean ± SD of 23.9 ± 6.0 cigarettes per day, were mostly male (32 men, 13 women), and had been smoking for an average ± SD of 17.9 ± 10.2 years. Subjects had a mean ± SD exhaled carbon monoxide of 19.0 ± 10.9 parts per million after 1 to 2 hours of abstinence, were moderately nicotine dependent (Fagerström Test for Nicotine Dependence mean ± SD score, 5.5 ± 2.0), and had minimal depression (mean ± SD total Hamilton Depression 17-item score, 1.8 ± 1.9) or anxiety (mean ± SD total Hamilton Anxiety score, 2.3 ± 2.5). There were no significant differences between the groups that did and did not smoke during scanning in any of the preceding variables (t tests; range of P values, .20 to .88).

GENETIC VARIANTS AND SMOKING-INDUCED DA RELEASE

The overall analysis of variance revealed a significant effect of genotype on percentage change in VCD/NAc BP (F4,30 = 6.5, P = .001). In examining the main effects of the 4 genotypes, subgroups based on the DAT (F1,30 = 4.9, P = .03) and DRD4 (F1,30 = 4.4, P = .04) VNTRs and the COMT (F1,30 = 10.2, P = .003) polymorphism differed in VCD/NAc BP percentage change in subjects who smoked during scanning, indicating that these genotypes are linked with the magnitude of smoking-induced DA release. In examining percentage change in VCD/NAc BP (Table and Figure 2), subgroups with the 9/9 or 9/10 genotype of the DAT VNTR, those with fewer than 7 repeats of the DRD4 VNTR (DRD4.7−), and those with the Val/Val COMT genotype (rapid metabolizers) had greater changes in VCD/NAc BP than those with the alternate genotypes, indicating that these genotypes are linked with greater smoking-induced DA release. No differences between subgroups based on the Taq1 polymorphism were found (Table), and no significant differences between subgroups based on any of the 4 genotypes were found in baseline (prebreak) BP values (all P values >.25).

Table Graphic Jump LocationTable. Smoking-Induced Changes in Ventral Caudate/Nucleus Accumbens Raclopride Labeled With Radioactive Carbon (11C) Binding Potential for Subgroups of Smokers Based on Genotype
Place holder to copy figure label and caption
Figure 2.

Sample images from positron emission tomography with raclopride labeled with radioactive carbon (11C) for genotypes found to differentiate subjects with high vs low dopamine (DA) release. The 2 left columns demonstrate decreases in [11C]raclopride binding (a marker for DA release) with smoking (postbreak scans are decay corrected) for subjects with the 9-allele repeat of the dopamine transporter (DAT) gene, less than 7 repeats (DRD4.7−) for the DRD4 genotype, or the Val/Val genotype of the catechol-O-methyltransferase (COMT) polymorphism. The 2 right columns demonstrate little change in [11C]raclopride binding in subjects with the alternate genotypes. VCD/NAc indicates ventral caudate/nucleus accumbens.

Graphic Jump Location

In examining the effect of the polymorphisms on clinical variables, subjects who were DRD4.7− smoked significantly fewer cigarettes per day than those who were DRD4.7+ (22.0 ± 4.1 vs 26.6 ± 4.9 cigarettes per day, respectively; t = 2.8, P = .01) (although the 2 subgroups did not have significantly different exhaled carbon monoxide levels at the time of scanning: 21.5 ± 10.7 vs 19.5 ± 11.9, t test, P = .60). Subjects who were DRD4.7− also had a greater reduction in mean UTS (craving) score from before to after smoking than DRD4.7+ subjects (−3.7 ± 1.6 vs −2.5 ± 2.2, respectively; t = 2.0, P = .05). No significant differences were found between subgroups based on the DRD4 genotype for number of years smoking or in the subgroups based on the other polymorphisms for the 3 clinical variables. Controlling for smoking habits (number of cigarettes per day) did not change the central results of the study with an overall significant analysis of covariance (F5,29 = 4.0, P = .007) and 3 genotype main effects (DRD4, F1,29 = 7.9, P = .009; DAT, F1,29 = 5.8, P = .02; and COMT, F1,29 = 5.0, P = .03) still being found.

STUDY OF SMOKING-INDUCED DA RELEASE

Subjects in this study who smoked during the break in scanning (n = 35) had a greater reduction in mean VCD/NAc BP than those who did not smoke (n = 10) (−8.4 ± 13.8% vs +1.8 ± 12.5%, t = 2.1, P = .04), indicating that smoking during scanning results in greater VCD/NAc DA release than taking a break in scanning without smoking. Results were similar for the left (−8.0 ± 14.8% vs +0.7 ± 13.9%, t test, P = .11) and right (−8.9 ± 14.5% vs +2.9 ± 11.5%, t test, P = .02) VCD/NAc. The exploratory VOIs had slightly weaker group differences that did not reach significance (−8.7 ± 12.6% vs −2.2 ± 15.7%, t = 1.4, P = .18, for the dorsal caudate and −7.9 ± 11.0% vs −1.5 ± 15.9%, t = 1.5, P = .15 for the dorsal putamen). Presmoking to postsmoking findings were larger than the frame-to-frame variability for the 2 prebreak (2.2%) and postbreak (1.8%) PET scans. Changes in cerebellar radioactivity from before to after the break were similar for the smoking and nonsmoking groups (−3.3 ± 14.0% vs −2.3 ± 8.8%, respectively, t test, P = .83).

There was a positive correlation between percentage change in VCD/NAc BP and change in UTS (craving) scores from before to after the break (r = 0.33, P = .05), indicating that greater smoking-induced DA release was associated with greater alleviation of craving. Correlations between change in VOI BP and change in UTS scores for the exploratory VOIs were not significant (r = 0.10, P = .55, for the dorsal caudate and r = 0.15, P = .39, for the dorsal putamen).

In this study, known genetic variants of the DA system were associated with varying levels of smoking-induced DA release in the VCD/NAc of tobacco-dependent smokers. Specifically, smokers with the 9-repeat allele of the DAT 3′ VNTR, DRD4.7−, or the Val/Val genotype of the COMT polymorphism had more smoking-induced DA release (measured indirectly) than those with the 10/10 DAT, DRD4.7+, or the Met COMT genotypes. Also, subjects with the DRD4.7− genotype smoked fewer cigarettes per day and had a greater reduction in craving from before to after smoking than DRD4.7+ subjects. As noted earlier in the article, the 10/10 genotype of DAT is potentially linked with decreased DAT density35,36 while the DRD4.7+ VNTR has been associated with reduced ability of DA to inhibit cAMP formation,51 reduced effectiveness of DA releasing medications,52 and smoking behavior53 and the Met allele of COMT is associated with slow DA catabolism,56 thereby indicating potential mechanisms for these genotypes to alter smoking-induced DA release.

Results of this study might be best understood from the perspective of the tonic-phasic model of DA function, with a recent study demonstrating that nicotine amplifies DA release during phasic activity in the striatum.92 The strongest associations observed with our paradigm are consistent with genetic effects on phasic DA regulation. Subjects with greater DAT densities (9 allele) and those with higher COMT activity (Val/Val) may have decreased tonic intrasynaptic DA levels, leading to increased smoking-induced phasic DA release. Autoinhibitory control (through DRD4) may also be important during phasic DA release. A recent literature review supports this theory by suggesting that subjects with the Val/Val genotype of COMT (rapid catabolizers) have lower tonic extraneuronal DA and higher phasic DA subcortically compared with subjects with the Met allele.59

In the present study, evidence was again found for human smoking-induced DA release; however, the magnitude of change in VCD/NAc BP was smaller in this larger subject sample (n = 35) scanned on a newer scanner than in our previous study15 (−8.4% for the new group compared with −25.9% to −36.6% for the ventral striatal regions of interest in the previous study15). While the new data call into question the magnitude of DA release with human smoking, they reaffirm the presence of smoking-induced DA release because 2 separate samples (using methodology blinded to subject condition) have now shown significant group differences between those who did and did not smoke during a 10-minute break in scanning in the hypothesized direction. The association between decreased craving and increased DA release was also found again, and all of these findings were more robust for the VCD/NAc than for dorsal basal ganglia VOIs.

This study should be interpreted in the context of several limitations. A first potential confound is that subjects were removed from the scanner and repositioned after smoking, which could potentially lead to differences in region placement on prebreak and postbreak scans because of imperfect repositioning. Although efforts were made to reposition the subjects precisely and regions were drawn on coregistered MRI images, it is possible that movement or imperfect alignment of scans led to slight differences in regions for the prebreak and postbreak scans. A second potential confound is that smoking might alter [11C]raclopride BP by effects on blood flow93,94 rather than DA release. In our previous15 and present studies, cerebellar activity (a measure of nonspecific binding) showed little change from before to after the break in either the nonsmoking or the smoking groups, indicating that our results were not strongly influenced by blood flow changes from smoking. Third, although subjects were monitored continuously during the break while they were standing in the outdoor area, subtle movements of hands or feet were not systematically examined. Rapid repetitive movements, such as finger tapping95 and foot extension/flexion96 (but not vigorous exercise97), have been shown to decrease [11C]raclopride BP and may present a confound if those who smoked differed from those who did not smoke in their movements. Studies comparing regular cigarette smoking with smoking of denicotinized cigarettes and/or nicotine administration would help clarify the role of movement in the present findings. And fourth, there is inherent variability in [11C]raclopride PET scanning due to technical issues in scanning and scan analysis87,98 and subject differences in radiotracer clearance,80 which may have increased variability for the BP measures found here.

In summary, this study demonstrates that genotypic differences may account for interindividual differences in smoking-induced DA release. In addition, the present study also demonstrates (indirectly) cigarette smoking–induced striatal DA release in humans. An association between decreased craving and increased DA concentration with smoking was also found. These results may have future implications for subtyping smokers based on clinical characteristics and possibly for identifying smokers who would be more likely to respond to dopaminergic pharmacotherapies or those therapies that affect the brain DA system.

Correspondence: Arthur L. Brody, MD, UCLA Department of Psychiatry and Biobehavioral Sciences, 300 UCLA Medical Plaza, Suite 2200, Los Angeles, CA 90095 (abrody@ucla.edu).

Submitted for Publication: April 1, 2005; final revision received August 1, 2005; accepted December 21, 2005.

Funding/Support: This study was supported by grants R01 DA15059, DA20872, and DA14093 from the National Institute on Drug Abuse (A.L.B. and E.D.L.), a Veterans Affairs Type I Merit Review Award (A.L.B.), grants 11RT-0024 and 10RT-0091 from the Tobacco-Related Disease Research Program (A.L.B. and E.D.L.), an Independent Investigator Award from the National Alliance for Research on Schizophrenia and Depression (A.L.B.), grant K24 MH01805 from the National Institute of Mental Health (J.T.M.), and contract DABT63-00-C-1003 from the Office of National Drug Control Policy (E.D.L.).

Previous Presentations: This study was presented in part at the Annual Meeting of the American College of Neuropsychopharmacology; December 12-16, 2004; San Juan, Puerto Rico; and the 11th Annual Duke Nicotine Research Conference; November 10, 2005; Durham, NC.

Acknowledgment: We thank Josephine Ribe and Michael Clark for technical assistance in performing positron emission tomography and magnetic resonance imaging scans, respectively.

Leshner  AIKoob  GF Drugs of abuse and the brain. Proc Assoc Am Physicians 1999;11199- 108
PubMed Link to Article
Koob  GF Drugs of abuse: anatomy, pharmacology and function of reward pathways. Trends Pharmacol Sci 1992;13177- 184
PubMed Link to Article
Gardner  EL Brain reward mechanisms. In:Lowinson  JHRuiz  PMillman  RBSubstance Abuse: A Comprehensive Textbook 2nd Baltimore, Md Williams and Wilkins1992;70- 99
Mayfield  RDPopp  RLMachu  TKLondon  EDGrant  SJMorgan  MJZukin  SR Neurobiology of drug abuse. In:Fogel  BSSchiffer  RBRao  SMeds.Neuropsychiatry 2nd Philadelphia, Pa Lippincott Williams & Wilkins2003;840- 892
Di Chiara  GImperato  A Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci U S A 1988;855274- 5278
PubMed Link to Article
Pontieri  FETanda  GOrzi  FDi Chiara  G Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature 1996;382255- 257
PubMed Link to Article
Sziraki  ILipovac  MNHashim  ASershen  HAllen  DCooper  TCzobor  PLajtha  A Differences in nicotine-induced dopamine release and nicotine pharmacokinetics between Lewis and Fischer 344 rats. Neurochem Res 2001;26609- 617
PubMed Link to Article
Damsma  GDay  JFibiger  HC Lack of tolerance to nicotine-induced dopamine release in the nucleus accumbens. Eur J Pharmacol 1989;168363- 368
PubMed Link to Article
Corrigall  WAFranklin  KBCoen  KMClarke  PB The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine. Psychopharmacology (Berl) 1992;107285- 289
PubMed Link to Article
Rowell  PPCarr  LAGarner  AC Stimulation of [3H]dopamine release by nicotine in rat nucleus accumbens. J Neurochem 1987;491449- 1454
PubMed Link to Article
Sakurai  YTakano  YKohjimoto  YHonda  KKamiya  HO Enhancement of [3H]dopamine release and its [3H]metabolites in rat striatum by nicotinic drugs. Brain Res 1982;24299- 106
PubMed Link to Article
Connelly  MSLittleton  JM Lack of stereoselectivity in ability of nicotine to release dopamine from rat synaptosomal preparations. J Neurochem 1983;411297- 1302
PubMed Link to Article
Marien  MBrien  JJhamandas  K Regional release of [3H]dopamine from rat brain in vitro: effects of opioids on release induced by potassium, nicotine, and L-glutamic acid. Can J Physiol Pharmacol 1983;6143- 60
PubMed Link to Article
Westfall  TCGrant  HPerry  H Release of dopamine and 5-hydroxytryptamine from rat striatal slices following activation of nicotinic cholinergic receptors. Gen Pharmacol 1983;14321- 325
PubMed Link to Article
Brody  ALOlmstead  RELondon  EDFarahi  JMeyer  JHGrossman  PLee  GSHuang  JHahn  ELMandelkern  MA Smoking-induced ventral striatum dopamine release. Am J Psychiatry 2004;1611211- 1218
PubMed Link to Article
Barrett  SPBoileau  IOkker  JPihl  RODagher  A The hedonic response to cigarette smoking is proportional to dopamine release in the human striatum as measured by positron emission tomography and [(11)C]raclopride. Synapse 2004;5465- 71
PubMed Link to Article
Batra  VPatkar  AABerrettini  WHWeinstein  SPLeone  FT The genetic determinants of smoking. Chest 2003;1231730- 1739
PubMed Link to Article
Pomerleau  OF Individual differences in sensitivity to nicotine: implications for genetic research on nicotine dependence. Behav Genet 1995;25161- 177
PubMed Link to Article
Pohjalainen  TRinne  JONagren  KLehikoinen  PAnttila  KSyvalahti  EKHietala  J The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers. Mol Psychiatry 1998;3256- 260
PubMed Link to Article
Jonsson  EGNothen  MMGrunhage  FFarde  LNakashima  YPropping  PSedvall  GC Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers. Mol Psychiatry 1999;4290- 296
PubMed Link to Article
Pohjalainen  TNagren  KSyvalahti  EKHietala  J The dopamine D2 receptor 5′-flanking variant, -141C Ins/Del, is not associated with reduced dopamine D2 receptor density in vivo. Pharmacogenetics 1999;9505- 509
PubMed
Laruelle  MGelernter  JInnis  RB D2 receptors binding potential is not affected by Taq1 polymorphism at the D2 receptor gene. Mol Psychiatry 1998;3261- 265
PubMed Link to Article
Nisell  MNomikos  GGSvensson  TH Systemic nicotine-induced dopamine release in the rat nucleus accumbens is regulated by nicotinic receptors in the ventral tegmental area. Synapse 1994;1636- 44
PubMed Link to Article
Lanca  AJAdamson  KLCoen  KMChow  BLCorrigall  WA The pedunculopontine tegmental nucleus and the role of cholinergic neurons in nicotine self-administration in the rat: a correlative neuroanatomical and behavioral study. Neuroscience 2000;96735- 742
PubMed Link to Article
Uhl  GRLin  Z The top 20 dopamine transporter mutants: structure-function relationships and cocaine actions. Eur J Pharmacol 2003;47971- 82
PubMed Link to Article
Bergson  CLevenson  RGoldman-Rakic  PSLidow  MS Dopamine receptor-interacting proteins: the Ca(2+) connection in dopamine signaling. Trends Pharmacol Sci 2003;24486- 492
PubMed Link to Article
Hamada  MHigashi  HNairn  ACGreengard  PNishi  A Differential regulation of dopamine D1 and D2 signaling by nicotine in neostriatal neurons. J Neurochem 2004;901094- 1103
PubMed Link to Article
Wong  AHCVan Tol  HHM The dopamine D-4 receptors and mechanisms of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry 2003;271091- 1099
PubMed Link to Article
Kopin  IJ Monoamine oxidase and catecholamine metabolism. J Neural Transm Suppl 1994;4157- 67
PubMed
Vandenbergh  DJPersico  AMHawkins  ALGriffin  CALi  XJabs  EWUhl  GR Human dopamine transporter gene (DAT1) maps to chromosome 5p15.3 and displays a VNTR. Genomics 1992;141104- 1106
PubMed Link to Article
Comings  DEWu  SChiu  CRing  RHGade  RAhn  CMacMurray  JPDietz  GMuhleman  D Polygenic inheritance of Tourette syndrome, stuttering, attention deficit hyperactivity, conduct, and oppositional defiant disorder: the additive and subtractive effect of the three dopaminergic genes, DRD2, D beta H, and DAT1. Am J Med Genet 1996;67264- 288
PubMed Link to Article
Kahn  RSKhoury  JNichols  WCLanphear  BP Role of dopamine transporter genotype and maternal prenatal smoking in childhood hyperactive-impulsive, inattentive, and oppositional behaviors. J Pediatr 2003;143104- 110
PubMed Link to Article
Samochowiec  JRybakowski  FCzerski  PZakrzewska  MStepien  GPelka-Wysiecka  JHorodnicki  JRybakowski  JKHauser  J Polymorphisms in the dopamine, serotonin, and norepinephrine transporter genes and their relationship to temperamental dimensions measured by the Temperament and Character Inventory in healthy volunteers. Neuropsychobiology 2001;43248- 253
PubMed Link to Article
Heinz  AGoldman  DJones  DWPalmour  RHommer  DGorey  JGLee  KSLinnoila  MWeinberger  DR Genotype influences in vivo dopamine transporter availability in human striatum. Neuropsychopharmacology 2000;22133- 139
PubMed Link to Article
Jacobsen  LKStaley  JKZoghbi  SSSeibyl  JPKosten  TRInnis  RBGelernter  J Prediction of dopamine transporter binding availability by genotype: a preliminary report. Am J Psychiatry 2000;1571700- 1703
PubMed Link to Article
van Dyck  CHMalison  RTJacobsen  LKSeibyl  JPStaley  JKLaruelle  MBaldwin  RMInnis  RBGelernter  J Increased dopamine transporter availability associated with the 9-repeat allele of the SLC6A3 gene. J Nucl Med 2005;46745- 751
PubMed
Martinez  DGelernter  JAbi-Dargham  Avan Dyck  CHKegeles  LInnis  RBLaruelle  M The variable number of tandem repeats polymorphism of the dopamine transporter gene is not associated with significant change in dopamine transporter phenotype in humans. Neuropsychopharmacology 2001;24553- 560
PubMed Link to Article
Lynch  DRMozley  PDSokol  SMaas  NMBalcer  LJSiderowf  AD Lack of effect of polymorphisms in dopamine metabolism related genes on imaging of TRODAT-1 in striatum of asymptomatic volunteers and patients with Parkinson's disease. Mov Disord 2003;18804- 812
PubMed Link to Article
Contin  MMartinelli  PMochi  MAlbani  FRiva  RScaglione  CDondi  MFanti  SPettinato  CBaruzzi  A Dopamine transporter gene polymorphism, spect imaging, and levodopa response in patients with Parkinson disease. Clin Neuropharmacol 2004;27111- 115
PubMed Link to Article
Thompson  JThomas  NSingleton  APiggott  MLloyd  SPerry  EKMorris  CMPerry  RHFerrier  INCourt  JA D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele. Pharmacogenetics 1997;7479- 484
PubMed Link to Article
Noble  EPBlum  KRitchie  TMontgomery  ASheridan  PJ Allelic association of the D2 dopamine receptor gene with receptor-binding characteristics in alcoholism. Arch Gen Psychiatry 1991;48648- 654
PubMed Link to Article
Ritchie  TNoble  EP Association of seven polymorphisms of the D2 dopamine receptor gene with brain receptor-binding characteristics. Neurochem Res 2003;2873- 82
PubMed Link to Article
Comings  DEFerry  LBradshaw-Robinson  SBurchette  RChiu  CMuhleman  D The dopamine D2 receptor (DRD2) gene: a genetic risk factor in smoking. Pharmacogenetics 1996;673- 79
PubMed Link to Article
Audrain-McGovern  JLerman  CWileyto  EPRodriguez  DShields  PG Interacting effects of genetic predisposition and depression on adolescent smoking progression. Am J Psychiatry 2004;1611224- 1230
PubMed Link to Article
David  SPNiaura  RPapandonatos  GDShadel  WGBurkholder  GJBritt  DMDay  AStumpff  JHutchison  KMurphy  MJohnstone  EGriffiths  SEWalton  RT Does the DRD2-Taq1 A polymorphism influence treatment response to bupropion hydrochloride for reduction of the nicotine withdrawal syndrome? Nicotine Tob Res 2003;5935- 942
PubMed Link to Article
Swan  GEValdes  AMRing  HZKhroyan  TVJack  LMTon  CCCurry  SJMcAfee  T Dopamine receptor DRD2 genotype and smoking cessation outcome following treatment with bupropion SR. Pharmacogenomics J 2005;521- 29
Link to Article
Cinciripini  PWetter  DTomlinson  GTsoh  JDe Moor  CCinciripini  LMinna  J The effects of the DRD2 polymorphism on smoking cessation and negative affect: evidence for a pharmacogenetic effect on mood. Nicotine Tob Res 2004;6229- 239
PubMed Link to Article
Lerman  CBerrettini  WPinto  APatterson  FCrystal-Mansour  SWileyto  EPRestine  SLLeonard  DGShields  PGEpstein  LH Changes in food reward following smoking cessation: a pharmacogenetic investigation. Psychopharmacology (Berl) 2004;174571- 577
PubMed Link to Article
Tang  LTodd  RDO’Malley  KL Dopamine D2 and D3 receptors inhibit dopamine release. J Pharmacol Exp Ther 1994;270475- 479
PubMed
Pothos  ENPrzedborski  SDavila  VSchmitz  YSulzer  D D2-Like dopamine autoreceptor activation reduces quantal size in PC12 cells. J Neurosci 1998;185575- 5585
PubMed
Asghari  VSanyal  SBuchwaldt  SPaterson  AJovanovic  VVan Tol  HH Modulation of intracellular cyclic AMP levels by different human dopamine D4 receptor variants. J Neurochem 1995;651157- 1165
PubMed Link to Article
Seeger  GSchloss  PSchmidt  MH Marker gene polymorphisms in hyperkinetic disorder: predictors of clinical response to treatment with methylphenidate? Neurosci Lett 2001;31345- 48
PubMed Link to Article
Shields  PGLerman  CAudrain  JBowman  EDMain  DBoyd  NRCaporaso  NE Dopamine D4 receptors and the risk of cigarette smoking in African-Americans and Caucasians. Cancer Epidemiol Biomarkers Prev 1998;7453- 458
PubMed
Feldpausch  DLNeedham  LMStone  MPAlthaus  JSYamamoto  BKSvensson  KAMerchant  KM The role of dopamine D4 receptor in the induction of behavioral sensitization to amphetamine and accompanying biochemical and molecular adaptations. J Pharmacol Exp Ther 1998;286497- 508
PubMed
Broderick  PAPiercey  MF Clozapine, haloperidol, and the D4 antagonist PNU-101387G: in vivo effects on mesocortical, mesolimbic, and nigrostriatal dopamine and serotonin release. J Neural Transm 1998;105749- 767
PubMed Link to Article
Lachman  HMPapolos  DFSaito  TYu  YMSzumlanski  CLWeinshilboum  RM Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 1996;6243- 250
PubMed Link to Article
Vandenbergh  DJRodriguez  LAMiller  ITUhl  GRLachman  HM High-activity catechol-O-methyltransferase allele is more prevalent in polysubstance abusers. Am J Med Genet 1997;74439- 442
PubMed Link to Article
Tsai  SJHong  CJYu  YWChen  TJ Association study of catechol-O-methyltransferase gene and dopamine D4 receptor gene polymorphisms and personality traits in healthy young Chinese females. Neuropsychobiology 2004;50153- 156
PubMed Link to Article
Bilder  RMVolavka  JLachman  HMGrace  AA The catechol-o-methyltransferase polymorphism: relations to the tonic-phasic dopamine hypothesis and neuropsychiatric phenotypes. Neuropsychopharmacology 2004;291943- 1961
PubMed Link to Article
Munafo  MClark  TJohnstone  EMurphy  MWalton  R The genetic basis for smoking behavior: a systematic review and meta-analysis. Nicotine Tob Res 2004;6583- 597
PubMed Link to Article
Li  MDMa  JZBeuten  J Progress in searching for susceptibility loci and genes for smoking-related behaviour. Clin Genet 2004;66382- 392
PubMed Link to Article
Feng  YNiu  TXing  HXu  XChen  CPeng  SWang  LLaird  NXu  X A common haplotype of the nicotine acetylcholine receptor alpha 4 subunit gene is associated with vulnerability to nicotine addiction in men. Am J Hum Genet 2004;75112- 121
PubMed Link to Article
Johnstone  ECYudkin  PLHey  KRoberts  SJWelch  SJMurphy  MFGriffiths  SEWalton  RT Genetic variation in dopaminergic pathways and short-term effectiveness of the nicotine patch. Pharmacogenetics 2004;1483- 90
PubMed Link to Article
Singleton  ABThomson  JHMorris  CMCourt  JALloyd  SCholerton  S Lack of association between the dopamine D2 receptor gene allele DRD2*A1 and cigarette smoking in a United Kingdom population. Pharmacogenetics 1998;8125- 128
PubMed Link to Article
Bierut  LJRice  JPEdenberg  HJGoate  AForoud  TCloninger  CRBegleiter  HConneally  PMCrowe  RRHesselbrock  VLi  TKNurnberger  JI  JrPorjesz  BSchuckit  MAReich  T Family-based study of the association of the dopamine D2 receptor gene (DRD2) with habitual smoking. Am J Med Genet 2000;90299- 302
PubMed Link to Article
Jorm  AFHenderson  ASJacomb  PAChristensen  HKorten  AERodgers  BTan  XEasteal  S Association of smoking and personality with a polymorphism of the dopamine transporter gene: results from a community survey. Am J Med Genet 2000;96331- 334
PubMed Link to Article
David  SPJohnstone  EGriffiths  SEMurphy  MYudkin  PMant  DWalton  R No association between functional catechol O-methyl transferase 1947A>G polymorphism and smoking initiation, persistent smoking or smoking cessation. Pharmacogenetics 2002;12265- 268
PubMed Link to Article
Lerman  CCaporaso  NEAudrain  JMain  DBowman  EDLockshin  BBoyd  NRShields  PG Evidence suggesting the role of specific genetic factors in cigarette smoking. Health Psychol 1999;1814- 20
PubMed Link to Article
Vandenbergh  DJBennett  CJGrant  MDStrasser  AAO'Connor  RStauffer  RLVogler  GPKozlowski  LT Smoking status and the human dopamine transporter variable number of tandem repeats (VNTR) polymorphism: failure to replicate and finding that never-smokers may be different. Nicotine Tob Res 2002;4333- 340
PubMed Link to Article
Lerman  CSwan  GE Non-replication of genetic association studies: is DAT all, folks? Nicotine Tob Res 2002;4247- 249
PubMed Link to Article
Sabol  SZNelson  MLFisher  CGunzerath  LBrody  CLHu  SSirota  LAMarcus  SEGreenberg  BDLucas  FRBenjamin  JMurphy  DLHamer  DH A genetic association for cigarette smoking behavior. Health Psychol 1999;187- 13
PubMed Link to Article
First  MBSpitzer  RLGibbon  MWilliams  JBW Structured Clinical Interview for DSM-IV Axis I Disorders: Patient Edition (SCID-I/P, version 2.0).  New York, NY Biometrics Research, New York State Psychiatric Institute1995;
Fagerström  KO Measuring the degree of physical dependence to tobacco smoking with reference to individualization of treatment. Addict Behav 1978;3235- 241
PubMed Link to Article
Heatherton  TFKozlowski  LTFrecker  RCFagerström  KO The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict 1991;861119- 1127
PubMed Link to Article
Jarvik  MEMadsen  DCOlmstead  REIwamoto-Schaap  PNElins  JLBenowitz  NL Nicotine blood levels and subjective craving for cigarettes. Pharmacol Biochem Behav 2000;66553- 558
PubMed Link to Article
Spielberger  C Manual for the State-Trait Anxiety Inventory.  Palo Alto, Calif Consulting Psychologists Press1983;
Hamilton  M Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967;6278- 296
PubMed Link to Article
Hamilton  M Diagnosis and rating of anxiety. Br J Psychiatry 1969;376- 79
Carson  REBreier  Ade Bartolomeis  ASaunders  RCSu  TPSchmall  BDer  MGPickar  DEckelman  WC Quantification of amphetamine-induced changes in [11C]raclopride binding with continuous infusion. J Cereb Blood Flow Metab 1997;17437- 447
PubMed Link to Article
Ito  HHietala  JBlomqvist  GHalldin  CFarde  L Comparison of the transient equilibrium and continuous infusion method for quantitative PET analysis of [11C]raclopride binding. J Cereb Blood Flow Metab 1998;18941- 950
PubMed Link to Article
Schuh  KJStitzer  ML Desire to smoke during spaced smoking intervals. Psychopharmacology (Berl) 1995;120289- 295
PubMed Link to Article
Farde  LHall  HEhrin  ESedvall  G Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. Science 1986;231258- 261
PubMed Link to Article
Ehrin  EGawell  LHogberg  TDepaulis  TStrom  P Synthesis of [methoxy-H-3]- and [methoxy-C-11]-labeled raclopride: specific dopamine-D2 receptor ligands. J Labelled Comp Radiopharm 1987;24931- 940
Link to Article
Woods  RPMazziotta  JCCherry  SR MRI-PET registration with automated algorithm. J Comput Assist Tomogr 1993;17536- 546
PubMed Link to Article
Lammertsma  AAHume  SP Simplified reference tissue model for PET receptor studies. Neuroimage 1996;4153- 158
PubMed Link to Article
Watabe  HEndres  CJBreier  ASchmall  BEckelman  WCCarson  RE Measurement of dopamine release with continuous infusion of [11C]raclopride: optimization and signal-to-noise considerations. J Nucl Med 2000;41522- 530
PubMed
Mawlawi  OMartinez  DSlifstein  MBroft  AChatterjee  RHwang  DRHuang  YSimpson  NNgo  KVan Heertum  RLaruelle  M Imaging human mesolimbic dopamine transmission with positron emission tomography: I. Accuracy and precision of D(2) receptor parameter measurements in ventral striatum. J Cereb Blood Flow Metab 2001;211034- 1057
PubMed Link to Article
Imperato  AMulas  ADi Chiara  G Nicotine preferentially stimulates dopamine release in the limbic system of freely moving rats. Eur J Pharmacol 1986;132337- 338
PubMed Link to Article
Benwell  MEBalfour  DJ Regional variation in the effects of nicotine on catecholamine overflow in rat brain. Eur J Pharmacol 1997;32513- 20
PubMed Link to Article
Janhunen  SAhtee  L Comparison of the effects of nicotine and epibatidine on the striatal extracellular dopamine. Eur J Pharmacol 2004;494167- 177
PubMed Link to Article
Marenco  SCarson  REBerman  KFHerscovitch  PWeinberger  DR Nicotine-induced dopamine release in primates measured with [C-11]raclopride PET. Neuropsychopharmacology 2004;29259- 268
PubMed Link to Article
Rice  MECragg  SJ Nicotine amplifies reward-related dopamine signals in striatum. Nat Neurosci 2004;7583- 584
PubMed Link to Article
Mathew  RJWilson  WH Substance abuse and cerebral blood flow. Am J Psychiatry 1991;148292- 305
PubMed
Boyajian  RAOtis  SM Acute effects of smoking on human cerebral blood flow: a transcranial Doppler ultrasonography study. J Neuroimaging 2000;10204- 208
PubMed
Goerendt  IKMessa  CLawrence  ADGrasby  PMPiccini  PBrooks  DJ Dopamine release during sequential finger movements in health and Parkinson's disease: a PET study. Brain 2003;126312- 325
PubMed Link to Article
Ouchi  YYoshikawa  EFutatsubashi  MOkada  HTorizuka  TSakamoto  M Effect of simple motor performance on regional dopamine release in the striatum in Parkinson disease patients and healthy subjects: a positron emission tomography study. J Cereb Blood Flow Metab 2002;22746- 752
PubMed Link to Article
Wang  GJVolkow  NDFowler  JSFranceschi  DLogan  JPappas  NRWong  CTNetusil  N PET studies of the effects of aerobic exercise on human striatal dopamine release. J Nucl Med 2000;411352- 1356
PubMed
Volkow  NDFowler  JSWang  GJDewey  SLSchlyer  DMacGregor  RLogan  JAlexoff  DShea  CHitzemann  R Reproducibility of repeated measures of carbon-11-raclopride binding in the human brain. J Nucl Med 1993;34609- 613
PubMed

Figures

Place holder to copy figure label and caption
Figure 1.

Magnetic resonance image (MRI)/positron emission tomography (PET) coregistration, showing regions of interest drawn on MRI and transferred to a coregistered PET image with raclopride labeled with radioactive carbon (11C). VCD/NAc indicates ventral caudate/nucleus accumbens.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.

Sample images from positron emission tomography with raclopride labeled with radioactive carbon (11C) for genotypes found to differentiate subjects with high vs low dopamine (DA) release. The 2 left columns demonstrate decreases in [11C]raclopride binding (a marker for DA release) with smoking (postbreak scans are decay corrected) for subjects with the 9-allele repeat of the dopamine transporter (DAT) gene, less than 7 repeats (DRD4.7−) for the DRD4 genotype, or the Val/Val genotype of the catechol-O-methyltransferase (COMT) polymorphism. The 2 right columns demonstrate little change in [11C]raclopride binding in subjects with the alternate genotypes. VCD/NAc indicates ventral caudate/nucleus accumbens.

Graphic Jump Location

Tables

Table Graphic Jump LocationTable. Smoking-Induced Changes in Ventral Caudate/Nucleus Accumbens Raclopride Labeled With Radioactive Carbon (11C) Binding Potential for Subgroups of Smokers Based on Genotype

References

Leshner  AIKoob  GF Drugs of abuse and the brain. Proc Assoc Am Physicians 1999;11199- 108
PubMed Link to Article
Koob  GF Drugs of abuse: anatomy, pharmacology and function of reward pathways. Trends Pharmacol Sci 1992;13177- 184
PubMed Link to Article
Gardner  EL Brain reward mechanisms. In:Lowinson  JHRuiz  PMillman  RBSubstance Abuse: A Comprehensive Textbook 2nd Baltimore, Md Williams and Wilkins1992;70- 99
Mayfield  RDPopp  RLMachu  TKLondon  EDGrant  SJMorgan  MJZukin  SR Neurobiology of drug abuse. In:Fogel  BSSchiffer  RBRao  SMeds.Neuropsychiatry 2nd Philadelphia, Pa Lippincott Williams & Wilkins2003;840- 892
Di Chiara  GImperato  A Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci U S A 1988;855274- 5278
PubMed Link to Article
Pontieri  FETanda  GOrzi  FDi Chiara  G Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature 1996;382255- 257
PubMed Link to Article
Sziraki  ILipovac  MNHashim  ASershen  HAllen  DCooper  TCzobor  PLajtha  A Differences in nicotine-induced dopamine release and nicotine pharmacokinetics between Lewis and Fischer 344 rats. Neurochem Res 2001;26609- 617
PubMed Link to Article
Damsma  GDay  JFibiger  HC Lack of tolerance to nicotine-induced dopamine release in the nucleus accumbens. Eur J Pharmacol 1989;168363- 368
PubMed Link to Article
Corrigall  WAFranklin  KBCoen  KMClarke  PB The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine. Psychopharmacology (Berl) 1992;107285- 289
PubMed Link to Article
Rowell  PPCarr  LAGarner  AC Stimulation of [3H]dopamine release by nicotine in rat nucleus accumbens. J Neurochem 1987;491449- 1454
PubMed Link to Article
Sakurai  YTakano  YKohjimoto  YHonda  KKamiya  HO Enhancement of [3H]dopamine release and its [3H]metabolites in rat striatum by nicotinic drugs. Brain Res 1982;24299- 106
PubMed Link to Article
Connelly  MSLittleton  JM Lack of stereoselectivity in ability of nicotine to release dopamine from rat synaptosomal preparations. J Neurochem 1983;411297- 1302
PubMed Link to Article
Marien  MBrien  JJhamandas  K Regional release of [3H]dopamine from rat brain in vitro: effects of opioids on release induced by potassium, nicotine, and L-glutamic acid. Can J Physiol Pharmacol 1983;6143- 60
PubMed Link to Article
Westfall  TCGrant  HPerry  H Release of dopamine and 5-hydroxytryptamine from rat striatal slices following activation of nicotinic cholinergic receptors. Gen Pharmacol 1983;14321- 325
PubMed Link to Article
Brody  ALOlmstead  RELondon  EDFarahi  JMeyer  JHGrossman  PLee  GSHuang  JHahn  ELMandelkern  MA Smoking-induced ventral striatum dopamine release. Am J Psychiatry 2004;1611211- 1218
PubMed Link to Article
Barrett  SPBoileau  IOkker  JPihl  RODagher  A The hedonic response to cigarette smoking is proportional to dopamine release in the human striatum as measured by positron emission tomography and [(11)C]raclopride. Synapse 2004;5465- 71
PubMed Link to Article
Batra  VPatkar  AABerrettini  WHWeinstein  SPLeone  FT The genetic determinants of smoking. Chest 2003;1231730- 1739
PubMed Link to Article
Pomerleau  OF Individual differences in sensitivity to nicotine: implications for genetic research on nicotine dependence. Behav Genet 1995;25161- 177
PubMed Link to Article
Pohjalainen  TRinne  JONagren  KLehikoinen  PAnttila  KSyvalahti  EKHietala  J The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers. Mol Psychiatry 1998;3256- 260
PubMed Link to Article
Jonsson  EGNothen  MMGrunhage  FFarde  LNakashima  YPropping  PSedvall  GC Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers. Mol Psychiatry 1999;4290- 296
PubMed Link to Article
Pohjalainen  TNagren  KSyvalahti  EKHietala  J The dopamine D2 receptor 5′-flanking variant, -141C Ins/Del, is not associated with reduced dopamine D2 receptor density in vivo. Pharmacogenetics 1999;9505- 509
PubMed
Laruelle  MGelernter  JInnis  RB D2 receptors binding potential is not affected by Taq1 polymorphism at the D2 receptor gene. Mol Psychiatry 1998;3261- 265
PubMed Link to Article
Nisell  MNomikos  GGSvensson  TH Systemic nicotine-induced dopamine release in the rat nucleus accumbens is regulated by nicotinic receptors in the ventral tegmental area. Synapse 1994;1636- 44
PubMed Link to Article
Lanca  AJAdamson  KLCoen  KMChow  BLCorrigall  WA The pedunculopontine tegmental nucleus and the role of cholinergic neurons in nicotine self-administration in the rat: a correlative neuroanatomical and behavioral study. Neuroscience 2000;96735- 742
PubMed Link to Article
Uhl  GRLin  Z The top 20 dopamine transporter mutants: structure-function relationships and cocaine actions. Eur J Pharmacol 2003;47971- 82
PubMed Link to Article
Bergson  CLevenson  RGoldman-Rakic  PSLidow  MS Dopamine receptor-interacting proteins: the Ca(2+) connection in dopamine signaling. Trends Pharmacol Sci 2003;24486- 492
PubMed Link to Article
Hamada  MHigashi  HNairn  ACGreengard  PNishi  A Differential regulation of dopamine D1 and D2 signaling by nicotine in neostriatal neurons. J Neurochem 2004;901094- 1103
PubMed Link to Article
Wong  AHCVan Tol  HHM The dopamine D-4 receptors and mechanisms of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry 2003;271091- 1099
PubMed Link to Article
Kopin  IJ Monoamine oxidase and catecholamine metabolism. J Neural Transm Suppl 1994;4157- 67
PubMed
Vandenbergh  DJPersico  AMHawkins  ALGriffin  CALi  XJabs  EWUhl  GR Human dopamine transporter gene (DAT1) maps to chromosome 5p15.3 and displays a VNTR. Genomics 1992;141104- 1106
PubMed Link to Article
Comings  DEWu  SChiu  CRing  RHGade  RAhn  CMacMurray  JPDietz  GMuhleman  D Polygenic inheritance of Tourette syndrome, stuttering, attention deficit hyperactivity, conduct, and oppositional defiant disorder: the additive and subtractive effect of the three dopaminergic genes, DRD2, D beta H, and DAT1. Am J Med Genet 1996;67264- 288
PubMed Link to Article
Kahn  RSKhoury  JNichols  WCLanphear  BP Role of dopamine transporter genotype and maternal prenatal smoking in childhood hyperactive-impulsive, inattentive, and oppositional behaviors. J Pediatr 2003;143104- 110
PubMed Link to Article
Samochowiec  JRybakowski  FCzerski  PZakrzewska  MStepien  GPelka-Wysiecka  JHorodnicki  JRybakowski  JKHauser  J Polymorphisms in the dopamine, serotonin, and norepinephrine transporter genes and their relationship to temperamental dimensions measured by the Temperament and Character Inventory in healthy volunteers. Neuropsychobiology 2001;43248- 253
PubMed Link to Article
Heinz  AGoldman  DJones  DWPalmour  RHommer  DGorey  JGLee  KSLinnoila  MWeinberger  DR Genotype influences in vivo dopamine transporter availability in human striatum. Neuropsychopharmacology 2000;22133- 139
PubMed Link to Article
Jacobsen  LKStaley  JKZoghbi  SSSeibyl  JPKosten  TRInnis  RBGelernter  J Prediction of dopamine transporter binding availability by genotype: a preliminary report. Am J Psychiatry 2000;1571700- 1703
PubMed Link to Article
van Dyck  CHMalison  RTJacobsen  LKSeibyl  JPStaley  JKLaruelle  MBaldwin  RMInnis  RBGelernter  J Increased dopamine transporter availability associated with the 9-repeat allele of the SLC6A3 gene. J Nucl Med 2005;46745- 751
PubMed
Martinez  DGelernter  JAbi-Dargham  Avan Dyck  CHKegeles  LInnis  RBLaruelle  M The variable number of tandem repeats polymorphism of the dopamine transporter gene is not associated with significant change in dopamine transporter phenotype in humans. Neuropsychopharmacology 2001;24553- 560
PubMed Link to Article
Lynch  DRMozley  PDSokol  SMaas  NMBalcer  LJSiderowf  AD Lack of effect of polymorphisms in dopamine metabolism related genes on imaging of TRODAT-1 in striatum of asymptomatic volunteers and patients with Parkinson's disease. Mov Disord 2003;18804- 812
PubMed Link to Article
Contin  MMartinelli  PMochi  MAlbani  FRiva  RScaglione  CDondi  MFanti  SPettinato  CBaruzzi  A Dopamine transporter gene polymorphism, spect imaging, and levodopa response in patients with Parkinson disease. Clin Neuropharmacol 2004;27111- 115
PubMed Link to Article
Thompson  JThomas  NSingleton  APiggott  MLloyd  SPerry  EKMorris  CMPerry  RHFerrier  INCourt  JA D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele. Pharmacogenetics 1997;7479- 484
PubMed Link to Article
Noble  EPBlum  KRitchie  TMontgomery  ASheridan  PJ Allelic association of the D2 dopamine receptor gene with receptor-binding characteristics in alcoholism. Arch Gen Psychiatry 1991;48648- 654
PubMed Link to Article
Ritchie  TNoble  EP Association of seven polymorphisms of the D2 dopamine receptor gene with brain receptor-binding characteristics. Neurochem Res 2003;2873- 82
PubMed Link to Article
Comings  DEFerry  LBradshaw-Robinson  SBurchette  RChiu  CMuhleman  D The dopamine D2 receptor (DRD2) gene: a genetic risk factor in smoking. Pharmacogenetics 1996;673- 79
PubMed Link to Article
Audrain-McGovern  JLerman  CWileyto  EPRodriguez  DShields  PG Interacting effects of genetic predisposition and depression on adolescent smoking progression. Am J Psychiatry 2004;1611224- 1230
PubMed Link to Article
David  SPNiaura  RPapandonatos  GDShadel  WGBurkholder  GJBritt  DMDay  AStumpff  JHutchison  KMurphy  MJohnstone  EGriffiths  SEWalton  RT Does the DRD2-Taq1 A polymorphism influence treatment response to bupropion hydrochloride for reduction of the nicotine withdrawal syndrome? Nicotine Tob Res 2003;5935- 942
PubMed Link to Article
Swan  GEValdes  AMRing  HZKhroyan  TVJack  LMTon  CCCurry  SJMcAfee  T Dopamine receptor DRD2 genotype and smoking cessation outcome following treatment with bupropion SR. Pharmacogenomics J 2005;521- 29
Link to Article
Cinciripini  PWetter  DTomlinson  GTsoh  JDe Moor  CCinciripini  LMinna  J The effects of the DRD2 polymorphism on smoking cessation and negative affect: evidence for a pharmacogenetic effect on mood. Nicotine Tob Res 2004;6229- 239
PubMed Link to Article
Lerman  CBerrettini  WPinto  APatterson  FCrystal-Mansour  SWileyto  EPRestine  SLLeonard  DGShields  PGEpstein  LH Changes in food reward following smoking cessation: a pharmacogenetic investigation. Psychopharmacology (Berl) 2004;174571- 577
PubMed Link to Article
Tang  LTodd  RDO’Malley  KL Dopamine D2 and D3 receptors inhibit dopamine release. J Pharmacol Exp Ther 1994;270475- 479
PubMed
Pothos  ENPrzedborski  SDavila  VSchmitz  YSulzer  D D2-Like dopamine autoreceptor activation reduces quantal size in PC12 cells. J Neurosci 1998;185575- 5585
PubMed
Asghari  VSanyal  SBuchwaldt  SPaterson  AJovanovic  VVan Tol  HH Modulation of intracellular cyclic AMP levels by different human dopamine D4 receptor variants. J Neurochem 1995;651157- 1165
PubMed Link to Article
Seeger  GSchloss  PSchmidt  MH Marker gene polymorphisms in hyperkinetic disorder: predictors of clinical response to treatment with methylphenidate? Neurosci Lett 2001;31345- 48
PubMed Link to Article
Shields  PGLerman  CAudrain  JBowman  EDMain  DBoyd  NRCaporaso  NE Dopamine D4 receptors and the risk of cigarette smoking in African-Americans and Caucasians. Cancer Epidemiol Biomarkers Prev 1998;7453- 458
PubMed
Feldpausch  DLNeedham  LMStone  MPAlthaus  JSYamamoto  BKSvensson  KAMerchant  KM The role of dopamine D4 receptor in the induction of behavioral sensitization to amphetamine and accompanying biochemical and molecular adaptations. J Pharmacol Exp Ther 1998;286497- 508
PubMed
Broderick  PAPiercey  MF Clozapine, haloperidol, and the D4 antagonist PNU-101387G: in vivo effects on mesocortical, mesolimbic, and nigrostriatal dopamine and serotonin release. J Neural Transm 1998;105749- 767
PubMed Link to Article
Lachman  HMPapolos  DFSaito  TYu  YMSzumlanski  CLWeinshilboum  RM Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 1996;6243- 250
PubMed Link to Article
Vandenbergh  DJRodriguez  LAMiller  ITUhl  GRLachman  HM High-activity catechol-O-methyltransferase allele is more prevalent in polysubstance abusers. Am J Med Genet 1997;74439- 442
PubMed Link to Article
Tsai  SJHong  CJYu  YWChen  TJ Association study of catechol-O-methyltransferase gene and dopamine D4 receptor gene polymorphisms and personality traits in healthy young Chinese females. Neuropsychobiology 2004;50153- 156
PubMed Link to Article
Bilder  RMVolavka  JLachman  HMGrace  AA The catechol-o-methyltransferase polymorphism: relations to the tonic-phasic dopamine hypothesis and neuropsychiatric phenotypes. Neuropsychopharmacology 2004;291943- 1961
PubMed Link to Article
Munafo  MClark  TJohnstone  EMurphy  MWalton  R The genetic basis for smoking behavior: a systematic review and meta-analysis. Nicotine Tob Res 2004;6583- 597
PubMed Link to Article
Li  MDMa  JZBeuten  J Progress in searching for susceptibility loci and genes for smoking-related behaviour. Clin Genet 2004;66382- 392
PubMed Link to Article
Feng  YNiu  TXing  HXu  XChen  CPeng  SWang  LLaird  NXu  X A common haplotype of the nicotine acetylcholine receptor alpha 4 subunit gene is associated with vulnerability to nicotine addiction in men. Am J Hum Genet 2004;75112- 121
PubMed Link to Article
Johnstone  ECYudkin  PLHey  KRoberts  SJWelch  SJMurphy  MFGriffiths  SEWalton  RT Genetic variation in dopaminergic pathways and short-term effectiveness of the nicotine patch. Pharmacogenetics 2004;1483- 90
PubMed Link to Article
Singleton  ABThomson  JHMorris  CMCourt  JALloyd  SCholerton  S Lack of association between the dopamine D2 receptor gene allele DRD2*A1 and cigarette smoking in a United Kingdom population. Pharmacogenetics 1998;8125- 128
PubMed Link to Article
Bierut  LJRice  JPEdenberg  HJGoate  AForoud  TCloninger  CRBegleiter  HConneally  PMCrowe  RRHesselbrock  VLi  TKNurnberger  JI  JrPorjesz  BSchuckit  MAReich  T Family-based study of the association of the dopamine D2 receptor gene (DRD2) with habitual smoking. Am J Med Genet 2000;90299- 302
PubMed Link to Article
Jorm  AFHenderson  ASJacomb  PAChristensen  HKorten  AERodgers  BTan  XEasteal  S Association of smoking and personality with a polymorphism of the dopamine transporter gene: results from a community survey. Am J Med Genet 2000;96331- 334
PubMed Link to Article
David  SPJohnstone  EGriffiths  SEMurphy  MYudkin  PMant  DWalton  R No association between functional catechol O-methyl transferase 1947A>G polymorphism and smoking initiation, persistent smoking or smoking cessation. Pharmacogenetics 2002;12265- 268
PubMed Link to Article
Lerman  CCaporaso  NEAudrain  JMain  DBowman  EDLockshin  BBoyd  NRShields  PG Evidence suggesting the role of specific genetic factors in cigarette smoking. Health Psychol 1999;1814- 20
PubMed Link to Article
Vandenbergh  DJBennett  CJGrant  MDStrasser  AAO'Connor  RStauffer  RLVogler  GPKozlowski  LT Smoking status and the human dopamine transporter variable number of tandem repeats (VNTR) polymorphism: failure to replicate and finding that never-smokers may be different. Nicotine Tob Res 2002;4333- 340
PubMed Link to Article
Lerman  CSwan  GE Non-replication of genetic association studies: is DAT all, folks? Nicotine Tob Res 2002;4247- 249
PubMed Link to Article
Sabol  SZNelson  MLFisher  CGunzerath  LBrody  CLHu  SSirota  LAMarcus  SEGreenberg  BDLucas  FRBenjamin  JMurphy  DLHamer  DH A genetic association for cigarette smoking behavior. Health Psychol 1999;187- 13
PubMed Link to Article
First  MBSpitzer  RLGibbon  MWilliams  JBW Structured Clinical Interview for DSM-IV Axis I Disorders: Patient Edition (SCID-I/P, version 2.0).  New York, NY Biometrics Research, New York State Psychiatric Institute1995;
Fagerström  KO Measuring the degree of physical dependence to tobacco smoking with reference to individualization of treatment. Addict Behav 1978;3235- 241
PubMed Link to Article
Heatherton  TFKozlowski  LTFrecker  RCFagerström  KO The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict 1991;861119- 1127
PubMed Link to Article
Jarvik  MEMadsen  DCOlmstead  REIwamoto-Schaap  PNElins  JLBenowitz  NL Nicotine blood levels and subjective craving for cigarettes. Pharmacol Biochem Behav 2000;66553- 558
PubMed Link to Article
Spielberger  C Manual for the State-Trait Anxiety Inventory.  Palo Alto, Calif Consulting Psychologists Press1983;
Hamilton  M Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967;6278- 296
PubMed Link to Article
Hamilton  M Diagnosis and rating of anxiety. Br J Psychiatry 1969;376- 79
Carson  REBreier  Ade Bartolomeis  ASaunders  RCSu  TPSchmall  BDer  MGPickar  DEckelman  WC Quantification of amphetamine-induced changes in [11C]raclopride binding with continuous infusion. J Cereb Blood Flow Metab 1997;17437- 447
PubMed Link to Article
Ito  HHietala  JBlomqvist  GHalldin  CFarde  L Comparison of the transient equilibrium and continuous infusion method for quantitative PET analysis of [11C]raclopride binding. J Cereb Blood Flow Metab 1998;18941- 950
PubMed Link to Article
Schuh  KJStitzer  ML Desire to smoke during spaced smoking intervals. Psychopharmacology (Berl) 1995;120289- 295
PubMed Link to Article
Farde  LHall  HEhrin  ESedvall  G Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. Science 1986;231258- 261
PubMed Link to Article
Ehrin  EGawell  LHogberg  TDepaulis  TStrom  P Synthesis of [methoxy-H-3]- and [methoxy-C-11]-labeled raclopride: specific dopamine-D2 receptor ligands. J Labelled Comp Radiopharm 1987;24931- 940
Link to Article
Woods  RPMazziotta  JCCherry  SR MRI-PET registration with automated algorithm. J Comput Assist Tomogr 1993;17536- 546
PubMed Link to Article
Lammertsma  AAHume  SP Simplified reference tissue model for PET receptor studies. Neuroimage 1996;4153- 158
PubMed Link to Article
Watabe  HEndres  CJBreier  ASchmall  BEckelman  WCCarson  RE Measurement of dopamine release with continuous infusion of [11C]raclopride: optimization and signal-to-noise considerations. J Nucl Med 2000;41522- 530
PubMed
Mawlawi  OMartinez  DSlifstein  MBroft  AChatterjee  RHwang  DRHuang  YSimpson  NNgo  KVan Heertum  RLaruelle  M Imaging human mesolimbic dopamine transmission with positron emission tomography: I. Accuracy and precision of D(2) receptor parameter measurements in ventral striatum. J Cereb Blood Flow Metab 2001;211034- 1057
PubMed Link to Article
Imperato  AMulas  ADi Chiara  G Nicotine preferentially stimulates dopamine release in the limbic system of freely moving rats. Eur J Pharmacol 1986;132337- 338
PubMed Link to Article
Benwell  MEBalfour  DJ Regional variation in the effects of nicotine on catecholamine overflow in rat brain. Eur J Pharmacol 1997;32513- 20
PubMed Link to Article
Janhunen  SAhtee  L Comparison of the effects of nicotine and epibatidine on the striatal extracellular dopamine. Eur J Pharmacol 2004;494167- 177
PubMed Link to Article
Marenco  SCarson  REBerman  KFHerscovitch  PWeinberger  DR Nicotine-induced dopamine release in primates measured with [C-11]raclopride PET. Neuropsychopharmacology 2004;29259- 268
PubMed Link to Article
Rice  MECragg  SJ Nicotine amplifies reward-related dopamine signals in striatum. Nat Neurosci 2004;7583- 584
PubMed Link to Article
Mathew  RJWilson  WH Substance abuse and cerebral blood flow. Am J Psychiatry 1991;148292- 305
PubMed
Boyajian  RAOtis  SM Acute effects of smoking on human cerebral blood flow: a transcranial Doppler ultrasonography study. J Neuroimaging 2000;10204- 208
PubMed
Goerendt  IKMessa  CLawrence  ADGrasby  PMPiccini  PBrooks  DJ Dopamine release during sequential finger movements in health and Parkinson's disease: a PET study. Brain 2003;126312- 325
PubMed Link to Article
Ouchi  YYoshikawa  EFutatsubashi  MOkada  HTorizuka  TSakamoto  M Effect of simple motor performance on regional dopamine release in the striatum in Parkinson disease patients and healthy subjects: a positron emission tomography study. J Cereb Blood Flow Metab 2002;22746- 752
PubMed Link to Article
Wang  GJVolkow  NDFowler  JSFranceschi  DLogan  JPappas  NRWong  CTNetusil  N PET studies of the effects of aerobic exercise on human striatal dopamine release. J Nucl Med 2000;411352- 1356
PubMed
Volkow  NDFowler  JSWang  GJDewey  SLSchlyer  DMacGregor  RLogan  JAlexoff  DShea  CHitzemann  R Reproducibility of repeated measures of carbon-11-raclopride binding in the human brain. J Nucl Med 1993;34609- 613
PubMed

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 109

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
JAMAevidence.com